Karl L.M. Rothweiler
Founder at Aglaia Management BV
Network origin in Karl L.M. Rothweiler first degree
Entity | Entity type | Industry | |
---|---|---|---|
Aglaia Management BV
Aglaia Management BV Investment ManagersFinance Aglaia Management BV is an independent venture capital investment firm headquartered in Bilthoven, the Netherlands. In 2003, Aglaia was co-founded by Mark Krul and Karl Rothweiler.
6
| Private Company | Investment Managers | 6 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Karl L.M. Rothweiler via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
ORCA Therapeutics BV
ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | Pharmaceuticals: Generic | Director/Board Member | |
NDDO Oncology BV
NDDO Oncology BV Miscellaneous Commercial ServicesCommercial Services Part of Syneos Health, Inc., NDDO Oncology BV provides product development support to pharmaceutical and biotechnology companies. The company is based in Amsterdam, Netherlands. The Dutch company was founded by Herbert Michael Pinedo. NDDO Oncology was acquired by Syneos Health NC LLC, part of Syneos Health, Inc. from December 31, 2010 on December 01, 2005. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
The European CanCer Organisation | Corporate Officer/Principal | ||
Rijksinstituut Voor Volksgezondheid En Milieu | Corporate Officer/Principal | ||
Netherlands Society of Gene Therapy | Corporate Secretary | ||
SomantiX BV
SomantiX BV Miscellaneous Commercial ServicesCommercial Services SomantiX BV develops imaging and therapy of cancer through targeting of tumor blood vessels. The firm offers Somantix’ screening platform which is in combination with the binder generation technologies that allows validation of new therapeutic targets and development of new cancer medicines. The company was founded in 2008 and is headquartered in Utrecht, Netherlands. | Miscellaneous Commercial Services | Chief Executive Officer | |
ISA Pharmaceuticals BV
ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer | |
MERUS N.V. | Biotechnology | Director/Board Member | |
University of Utrecht | College/University | Doctorate Degree | |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member | |
Cristal Delivery BV
Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | Biotechnology | Director/Board Member |
Statistics
International
Netherlands | 13 |
Belgium | 2 |
Switzerland | 2 |
United Kingdom | 2 |
Sectoral
Health Technology | 10 |
Commercial Services | 3 |
Consumer Services | 2 |
Operational
Director/Board Member | 12 |
Private Equity Investor | 5 |
Corporate Officer/Principal | 3 |
Chief Executive Officer | 3 |
Private Equity Analyst | 2 |
Most connected contacts
Insiders | |
---|---|
Mark R.L. Krul | 16 |
Eric van der Putten | 3 |
Sanne Weijzen | 2 |
Winald Gerritsen | 1 |
Ernst Geutjes | 1 |
Joost Ruitenberg | 1 |
- Stock Market
- Insiders
- Karl L.M. Rothweiler
- Company connections